[go: up one dir, main page]
More Web Proxy on the site http://driver.im/ Skip to main content

Advertisement

Springer Nature Link
Log in

Inactivation of p53 Sensitizes Astrocytic Glioma Cells to BCNU and Temozolomide, but not Cisplatin

  • Laboratory Investigation
  • Published:
Journal of Neuro-Oncology Aims and scope Submit manuscript

Summary

p53 inactivation sensitizes U87MG astrocytic glioma cells to 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) and temozolomide (TMZ), drugs used clinically to treat high-grade astrocytomas. In this report, we examined the effect of p53 inactivation on the chemosensitivity of two additional human astrocytic glioma cell lines, D54 and A172, in order to assess whether sensitization is a general property of astrocytic tumor cells. Compared to control cells with intact p53 function, derived lines in which p53 was inactivated displayed significantly reduced clonogenic survival after exposure to BCNU and TMZ. Sensitization to both BCNU and TMZ was associated with failure of p21WAF1 induction, lack of a sustained G2 cell cycle arrest and significant tumor cell death. These findings suggest that enhanced sensitivity to BCNU and TMZ is a general property of human astrocytic glioma cells in which p53 was disrupted. In contrast, p53 inactivation rendered D54 and U87MG cells significantly more resistant to cis-dichlorodiamminoplatinum (CDDP), another chemotherapeutic to which high-grade astrocytomas sometimes respond. These results indicate that p53 status influences the chemosensitivity of astrocytic glioma cells in a drug-type specific manner, a finding that may have implications for the selection of drug treatments for patients with astrocytic gliomas.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
£29.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price includes VAT (United Kingdom)

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

Abbreviations

BCNU:

1,3-bis (2-chloroethyl)-1-nitrosourea

CDDP:

cis-dichlorodiammine platinum(II)

TMZ:

temozolomide

LD:

lethal dose

FBS:

fetal bovine serum

ECL:

enhanced chemiluminescence

References

  1. AJ Levine (1997) ArticleTitlep53, the cellular gatekeeper for growth and division Cell 88 323–331 Occurrence Handle9039259

    PubMed  Google Scholar 

  2. M Hollstein D Sidransky B Vogelstein CC Harris (1991) ArticleTitlep53 mutations in human cancers Science 253 49–53 Occurrence Handle1905840

    PubMed  Google Scholar 

  3. AJ Giaccia MB Kastan (1998) ArticleTitleThe complexity of p53 modulation: emerging patterns from divergent signals Genes Dev 12 2973–2983 Occurrence Handle9765199

    PubMed  Google Scholar 

  4. B Vogelstein D Lane AJ Levine (2000) ArticleTitleSurfing the p53 network Nature 408 307–310

    Google Scholar 

  5. M Oren (1999) ArticleTitleRegulation of the p53 tumor suppressor protein J Biol Chem 274 36031–36034 Occurrence Handle10593882

    PubMed  Google Scholar 

  6. M Oren (2003) ArticleTitleDecision making by p53: life, death and cancer Cell Death Differ 10 431–442 Occurrence Handle10.1038/sj.cdd.4401183 Occurrence Handle12719720

    Article  PubMed  Google Scholar 

  7. O Bogler HJ Huang P Kleihues WK Cavenee (1995) ArticleTitleThe p53 gene and its role in human brain tumors Glia 15 308–327 Occurrence Handle10.1002/glia.440150311 Occurrence Handle8586466

    Article  PubMed  Google Scholar 

  8. M Tada R Matsumoto RD Iggo R Onimaru H Shirato Y Sawamura Y Shinohe (1998) ArticleTitleSelective sensitivity to radiation of cerebral glioblastomas harboring p53 mutations Cancer Res 58 1793–1797 Occurrence Handle9581814

    PubMed  Google Scholar 

  9. MC Schmidt S Antweiler N Urban W Mueller A Kuklik B Meyer-Puttlitz OD Wiestler DN Louis R Fimmers A Deimling Particlevon (2002) ArticleTitleImpact of genotype and morphology on the prognosis of glioblastoma J Neuropathol Exp Neurol 61 321–328 Occurrence Handle11939587

    PubMed  Google Scholar 

  10. EC Burton KR Lamborn P Forsyth J Scott J O’Campo J Uyehara-Lock M Prados M Berger S Passe J Uhm BP O’Neill RB Jenkins KD Aldape (2002) ArticleTitleAberrant p53, mdm2, and proliferation differ in glioblastomas from long-term compared with typical survivors Clin Cancer Res 8 180–187 Occurrence Handle11801556

    PubMed  Google Scholar 

  11. R Grant BC Liang MA Page DL Crane HS Greenberg L Junck (1995) ArticleTitleAge influences chemotherapy response in astrocytomas Neurology 45 929–933 Occurrence Handle7746409

    PubMed  Google Scholar 

  12. CL Nutt AF Chambers JG Cairncross (1996) ArticleTitleWild-type p53 renders mouse astrocytes resistant to 1,3-bis (2-chloroethyl)-1-nitrosourea despite the absent of a p53-dependent cell cycle arrest Cancer Res 56 2748–2751 Occurrence Handle8665508

    PubMed  Google Scholar 

  13. GW Xu CL Nutt MC Zlatescu M Keeney I Chin-Yee JG Cairncross (2001) ArticleTitleInactivation of p53 sensitizes U87MG glioma cells to 1,3-bis(2-chloroethyl)-1-nitrosourea Cancer Res 61 4155–4159 Occurrence Handle11358839

    PubMed  Google Scholar 

  14. Y Hirose MS Berger RO Pieper (2001) ArticleTitlep53 effects both the duration of G2/M arrest and the fate of temozolomide-treated human glioblastoma cells Cancer Res 61 1957–1963 Occurrence Handle11280752

    PubMed  Google Scholar 

  15. Y Wang S Zhu TF Cloughesy LM Liau PS Mischel (2004) ArticleTitlep53 disruption profoundly alters the response of human glioblastoma cells to DNA topoisomerase I inhibition Oncogene 23 1283–1290 Occurrence Handle10.1038/sj.onc.1207244 Occurrence Handle14961077

    Article  PubMed  Google Scholar 

  16. X Wang K Ohnishi A Takahashi T Ohnishi (1998) ArticleTitlePoly(ADP-ribosyl)ation is required for p53-dependent signal transduction induced by radiation Oncogene 17 2819–2825 Occurrence Handle10.1038/sj.onc.1202216 Occurrence Handle9879988

    Article  PubMed  Google Scholar 

  17. N Ishii D Maier A Merlo M Tada Y Sawamura AC Diserens EG Van Meir (1999) ArticleTitleFrequent co-alterations of TP53, p16/CDKN2A, p14ARF, PTEN tumor suppressor genes in human glioma cell lines Brain Pathol 9 469–479 Occurrence Handle10416987

    PubMed  Google Scholar 

  18. LJ Ostruszka DS Shewach (2000) ArticleTitleThe role of cell cycle progression in radiosensitization by 2′,2′-difluoro-2′-deoxycytidine Cancer Res 60 6080–6088 Occurrence Handle11085531

    PubMed  Google Scholar 

  19. T Shono PJ Tofilon TS Schaefer D Parikh TJ Liu FF Lang (2002) ArticleTitleApoptosis induced by adenovirus-mediated p53 gene transfer in human glioma correlates with site-specific phosphorylation Cancer Res 62 1069–1076 Occurrence Handle11861384

    PubMed  Google Scholar 

  20. B Vogelstein KW Kinzler (1992) ArticleTitlep53 function and dysfunction Cell 70 523–526 Occurrence Handle10.1016/0092-8674(92)90421-8 Occurrence Handle1505019

    Article  PubMed  Google Scholar 

  21. TD Kessis RJ Slebos WG Nelson MB Kastan BS Plunkett SM Han AT Lorincz L Hedrick KR Cho (1993) ArticleTitleHuman papillomavirus 16 E6 expression disrupts the p53-mediated cellular response to DNA damage Proc Natl Acad Sci USA 90 3988–3992 Occurrence Handle8387205

    PubMed  Google Scholar 

  22. JM Brown BG Wouters (1999) ArticleTitleApoptosis, p53, and tumor cell sensitivity to anticancer agents Cancer Res 59 1391–1399 Occurrence Handle10197600

    PubMed  Google Scholar 

  23. LL Vindelov IJ Christensen NI Nissen (1983) ArticleTitleA detergent–trypsin method for the preparation of nuclei for flow cytometric DNA analysis Cytometry 3 323–327 Occurrence Handle6188586

    PubMed  Google Scholar 

  24. CL Nutt M Noble AF Chambers JG Cairncross (2000) ArticleTitleDifferential expression of drug resistance genes and chemosensitivity in glial cell lineages correlate with differential response of oligodendrogliomas and astrocytomas to chemotherapy Cancer Res 60 4812–4818 Occurrence Handle10987291

    PubMed  Google Scholar 

  25. F Bunz PM Hwang C Torrance T Waldman Y Zhang L Dillehay J Williams C Lengauer KW Kinzler B Vogelstein (1999) ArticleTitleDisruption of p53 in human cancer cells alters the responses to therapeutic agents J Clin Invest 104 263–269 Occurrence Handle10430607

    PubMed  Google Scholar 

  26. M Weller (1998) ArticleTitlePredicting response to cancer chemotherapy: the role of p53 Cell Tissue Res 292 435–445 Occurrence Handle10.1007/s004410051072 Occurrence Handle9582400

    Article  PubMed  Google Scholar 

  27. WR Taylor GR Stark (2001) ArticleTitleRegulation of the G2/M transition by p53 Oncogene 20 1803–1815 Occurrence Handle10.1038/sj.onc.1204252 Occurrence Handle11313928

    Article  PubMed  Google Scholar 

  28. A Eastman (2004) ArticleTitleCell cycle checkpoints and their impact on anticancer therapeutic strategies J Cell Biochem 91 223–231 Occurrence Handle10.1002/jcb.10699 Occurrence Handle14743382

    Article  PubMed  Google Scholar 

  29. S Fan ML Smith DJ Rivet D Duba Q Zhan KW Kohn AJ Fornace SuffixJr. PM O’Connor (1995) ArticleTitleDisruption of p53 function sensitizes breast cancer MCF-7 cells to cisplatin and pentoxifylline Cancer Res 55 1649–1654 Occurrence Handle7712469

    PubMed  Google Scholar 

  30. SP Linke KC Clarkin GM Wahl (1997) ArticleTitlep53 mediates permanent arrest over multiple cell cycles in response to gamma-irradiation Cancer Res 57 1171–1179 Occurrence Handle9067289

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Departments of Oncology, University of Western, Ontario, Canada

    G. Wei Xu, Joe S. Mymryk & J. Gregory Cairncross

  2. Neuroscience Program, University of Western Ontario, Ontario, Canada

    G. Wei Xu, Joe S. Mymryk & J. Gregory Cairncross

  3. Departments of Microbiology & Immunology, University of Western Ontario, Ontario, Canada

    Joe S. Mymryk

  4. The Cancer Research Laboratories, London Regional Cancer Centre, London, Ontario, Canada

    G. Wei Xu & Joe S. Mymryk

  5. Department of Clinical Neurosciences, University of Calgary, Calgary, Alberta, Canada

    J. Gregory Cairncross

  6. Cairncoss Foothills Medical Centre, 1403 29th Street N.W., Calgary, T2N 2T9, Alberta, Canada

    J. Gregory Cairncross

Authors
  1. G. Wei Xu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Joe S. Mymryk
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. J. Gregory Cairncross
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to J. Gregory Cairncross.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Xu, G.W., Mymryk, J.S. & Cairncross, J.G. Inactivation of p53 Sensitizes Astrocytic Glioma Cells to BCNU and Temozolomide, but not Cisplatin. J Neurooncol 74, 141–149 (2005). https://doi.org/10.1007/s11060-004-6601-3

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11060-004-6601-3

Keywords

Search

Navigation